Bluebird Bio Inc (BLUE) 39.14 $BLUE
bluebird bio misses by $0.11, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 6:36AM CST
BLUE: 39.14 (-2.09)
bluebird bio Reports Fiscal Third Quarter 2014 Financial Results
Business Wire - Wed Nov 12, 6:01AM CST
bluebird bio, Inc. (Nasdaq:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today reported financial results and operational highlights for the quarter ended September 30, 2014.
BLUE: 39.14 (-2.09)
Is a Surprise Coming for bluebird bio (BLUE) This Earnings Season? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 7:51AM CST
bluebird bio has a favorable Zacks Rank and an ESP in positive territory, thus investors might want to consider this stock ahead of earnings.
BLUE: 39.14 (-2.09)
Release The Passion! Besado Tequila to make its debut Nov. 19 at the Boca Raton Blue Martini
ACCESSWIRE - Mon Nov 10, 8:33AM CST
SALT LAKE CITY, UT / ACCESSWIRE / November 11, 2014 / Top Shelf Brands Holdings, Inc.'s (a Nevada Corporation) (TEMN) management is pleased to announce that it has signed an agreement with Blue Martini, Inc. to co-promote the debut of Top Shelf's exciting new brand, the erotic herbal-infused Besado Tequila. The unveiling party will be held on Nov. 19 at the Blue Martini in Boca Raton.
BLUE: 39.14 (-2.09)
New finance chief at bluebird bio
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 7:56AM CST
BLUE: 39.14 (-2.09), IRWD: 13.13 (-0.36)
James M. DeTore joins bluebird bio as Chief Financial Officer
Business Wire - Mon Nov 10, 6:00AM CST
bluebird bio, Inc. (Nasdaq:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced that James M. DeTore is joining the company as its Chief Financial Officer and Treasurer and member of the company's leadership team.
BLUE: 39.14 (-2.09), IRWD: 13.13 (-0.36)
bluebird bio to Present at Three Upcoming Health Care Conferences
Business Wire - Fri Nov 07, 6:00AM CST
bluebird bio, Inc. (Nasdaq: BLUE) announces that management will present at the Credit Suisse First Boston Bank Health Care Conference on Thursday, November 13, 2014 at 8:00 AM (MST) at the Biltmore Hotel, Phoenix, Arizona. Management will also present at the Deutsche BioFEST Conference on Monday, December 1, 2014 at 9.50 AM (ET) at the Four Seasons Hotel, Boston, Massachusetts and at the Piper Jaffray Healthcare Conference on Tuesday, December 2, 2014 at 3.30 PM (ET) at the New York Palace Hotel, New York, New York.
BLUE: 39.14 (-2.09)
Update: New Patient Receiving BlueBird Gene Therapy Responding More Slowly
at The Street - Thu Nov 06, 10:31AM CST
The new clinical data on Bluebird's gene therapy is contained in a just-released abstract ahead of next month's American Society of Hematology (ASH) annual meeting.
BLUE: 39.14 (-2.09)
Bluebird Bio (BLUE) Highlighted As Weak On High Volume
at The Street - Thu Nov 06, 9:01AM CST
Trade-Ideas LLC identified bluebird bio (BLUE) as a weak on high relative volume candidate
BLUE: 39.14 (-2.09)
bluebird bio to Present LentiGlobin Clinical Data at the American Society of Hematology Conference
Business Wire - Thu Nov 06, 8:01AM CST
-- Data to be presented from the Northstar Study and from the HGB-205 Study
BLUE: 39.14 (-2.09)
Insider Trading Alert - BLUE, CHRW And BMY Traded By Insiders
at The Street - Wed Oct 29, 9:06AM CDT
Stocks with insider trader activity include BLUE, CHRW and BMY
BLUE: 39.14 (-2.09), CHRW: 73.07 (-0.04), BMY: 57.95 (+0.15)
Can the Uptrend Continue for Bluebird (BLUE)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 8:22AM CDT
Can the Uptrend Continue for Bluebird (BLUE)?
BLUE: 39.14 (-2.09)
Will Quest Diagnostics (DGX) Surprise Earnings in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 2:30PM CDT
Quest Diagnostics Inc. (DGX) is scheduled to report its third-quarter 2014 results before the opening bell on Oct 23.
BLUE: 39.14 (-2.09), MDVN: 106.90 (-0.31), PACB: 6.80 (-0.13), DGX: 62.41 (-1.36)
Will Zimmer (ZMH) Miss Earnings Estimates this Quarter? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 2:10PM CDT
Zimmer Holdings Inc. (ZMH) is scheduled to report its third-quarter 2014 results before the opening bell on Oct 23.
BLUE: 39.14 (-2.09), MDVN: 106.90 (-0.31), ZMH: 110.12 (-0.49), PACB: 6.80 (-0.13)
Will Boston Scientific (BSX) Surprise this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 2:20PM CDT
Boston Scientific Corporation (BSX) is scheduled to report its third-quarter 2014 results before the opening bell on Oct 22.
BLUE: 39.14 (-2.09), MDVN: 106.90 (-0.31), BSX: 13.36 (-0.05), PACB: 6.80 (-0.13)
InsiderInsights.com Daily Round Up 10/14/14: ALSN, ETE, AAMC, AGCO
InsiderInsights - at Seeking Alpha - Wed Oct 15, 10:08AM CDT
BLUE: 39.14 (-2.09), RDEN: 17.41 (-0.29), AGCO: 44.18 (+0.09), ALSN: 33.37 (+0.16), AAMC: 481.00 (-10.84), ETE: 61.69 (+0.77), BURL: 42.30 (+0.04), SHLD: 37.31 (-0.49), GOOG: 544.40 (-0.98), VNO: 107.58 (-0.57), OPK: 8.29 (-0.05), CUDA: 35.34 (+0.98), COST: 138.48 (-0.23), WMB: 54.05 (+0.17), FTK: 22.03 (+1.38), WAG: 66.93 (-0.03), SYK: 88.00 (-0.84)
bluebird bio Announces First Patient with Sickle Cell Disease Transplanted with LentiGlobin Gene Therapy
Business Wire - Tue Oct 14, 6:00AM CDT
bluebird bio, Inc. (Nasdaq: BLUE) a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced that the first subject with severe sickle cell disease has undergone infusion with bluebird bio's LentiGlobin BB305 drug product in an autologous hematopoietic stem cell transplantation. This patient is enrolled in the HGB-205 Study being conducted in Paris, France. bluebird has also opened a separate US-based trial (HGB-206) in the United States for the treatment of up to 8 severe sickle cell disease patients with the company's LentiGlobin BB305 drug product.
BLUE: 39.14 (-2.09)
Insider Trading Alert - BLUE, NVAX And SNCR Traded By Insiders
at The Street - Mon Oct 06, 9:15AM CDT
Stocks with insider trader activity include BLUE, NVAX and SNCR
BLUE: 39.14 (-2.09), SNCR: 48.38 (+0.42), NVAX: 5.28 (+0.09)
Acceleron Hit Over Competitive Concerns, But Investors Overlook Rest of Pipeline
at The Street - Thu Oct 02, 8:21AM CDT
An Acceleron update in December could reignite investor interest in the stock.
BLUE: 39.14 (-2.09), XLRN: 33.50 (-1.81)
Global Gene Therapy Market Outlook 2018
M2 - Wed Sep 17, 5:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bqlkd5/global_gene) has announced the addition of the "Global Gene Therapy Market Outlook 2018" report to their offering. Gene therapy is the treatment of a disease by replacing, altering, or supplementing a gene that is absent or abnormal and whose absence or abnormality is causing the disease. It has evolved as one of the most sought after research objectives for difficult to cure' diseases. The gene therapy market, presenting a few marketable products and being nascent in terms of revenue generation, holds tremendous growth potential. As per a new estimation carried out in our latest study, the global gene therapy industry has the potential to become a multi-million dollar industry by the end of 2018, as new products, especially those in the advanced stage of clinical studies or with pending approvals, may enter the market to boost the growth. Primarily, the gene therapy market is dominated by oncology applications with several companies and academic institutions focusing on novel and difficult to treat' cancers. Other therapeutic areas seeing developments in gene therapy include cardiac conditions, inherited blindness, genetic disorders and neurological diseases. An effective analysis of the key therapeutic areas has been included in the report. Also, a brief overview of the key geographies in the gene therapy market and the regulatory scenario governing the industry has been included to present a balanced outlook. Unlike other regions globally, the United States continues to have the maximum number of clinical trials in the gene therapy segment. This shows the country's potential to become a leader in gene therapy in the coming years. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Gene Therapy - An Introduction Classification of Gene Therapy Techniques Physical Methods of Gene Transfer - Electroporation - Hydrodynamic - Microinjection - Particle Bombardment - Ultrasound-mediated Transfection Vectors for Gene Therapy - Adenoviral Vectors - Adeno-associated Virus Vectors - Retroviral Vectors - Lentiviral Vectors - Plasmid DNA 4. Industry Trends and Drivers Industry Trends - Gene Silencing: Gaining Momentum - Advanced Therapies: Combining Gene Therapy and Stem Cell Technology - Immunodeficiency Syndromes: The Focus of Gene Therapy - Nanotechnology: Empowering Gene Therapy - Gene Therapy: A New Hope to Treat Blindness - Gene Therapy: Potential Cure for Cancer Market Drivers - Failure of Conventional Therapies to Treat Cancers - Entry of Gene Therapies in Developed Nations - Rising Incidence of Chronic and Life Threatening Diseases - Growing Interest of Venture Capital Firms 5. Market Restraints - High Cost of Treatment - Stringent Regulatory Laws & Safety Concerns - Pitfalls in Current Technique 6. Gene Therapy Market Outlook - Oncology - Infectious Diseases - Genetic Disorders - Cardiovascular Disorders - Diabetes Mellitus - Neurological Disorders 7. Gene Therapy Market - Regulatory Landscape 8. Advanced Gene Therapy Drugs - Collategene - Allovectin-7 - Generx - Glybera 9. Mergers and Acquisitions - Sangamo BioSciences to Acquire Gene Therapy Company Ceregene. - Baxter to Acquire Chatham Therapeutics - Bluebird Bio Acquired Privately Held Gene-Editing Company - Miltenyi Acquired Gene Therapy Assets from Lentigen - Dutch Player UniQure to Acquire InoCard GmbH for CHF Therapy. 10. Key Players Analysis (Business Description, Clinical Pipeline, Recent Developments, Strengths & Weaknesses, Key People) - Spark Therapeutics, LLC - ViroMed Co. Ltd. dba VM BioPharma - Advantagene Inc - Bluebird Bio - Sanofi - Genzyme - A Sanofi Company - Kolon Life Science - Vical Inc - Oxford BioMedica - Genethon For more information visit http://www.researchandmarkets.com/research/bq...lobal_gene
BLUE: 39.14 (-2.09), VICL: 1.12 (-0.02), SGMO: 11.21 (-0.52)
bluebird bio misses by $0.11, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 6:36AM CST
BLUE: 39.14 (-2.09)
bluebird bio Reports Fiscal Third Quarter 2014 Financial Results
Business Wire - Wed Nov 12, 6:01AM CST
bluebird bio, Inc. (Nasdaq:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today reported financial results and operational highlights for the quarter ended September 30, 2014.
BLUE: 39.14 (-2.09)
Is a Surprise Coming for bluebird bio (BLUE) This Earnings Season? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 7:51AM CST
bluebird bio has a favorable Zacks Rank and an ESP in positive territory, thus investors might want to consider this stock ahead of earnings.
BLUE: 39.14 (-2.09)
Release The Passion! Besado Tequila to make its debut Nov. 19 at the Boca Raton Blue Martini
ACCESSWIRE - Mon Nov 10, 8:33AM CST
SALT LAKE CITY, UT / ACCESSWIRE / November 11, 2014 / Top Shelf Brands Holdings, Inc.'s (a Nevada Corporation) (TEMN) management is pleased to announce that it has signed an agreement with Blue Martini, Inc. to co-promote the debut of Top Shelf's exciting new brand, the erotic herbal-infused Besado Tequila. The unveiling party will be held on Nov. 19 at the Blue Martini in Boca Raton.
BLUE: 39.14 (-2.09)
New finance chief at bluebird bio
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 7:56AM CST
BLUE: 39.14 (-2.09), IRWD: 13.13 (-0.36)
James M. DeTore joins bluebird bio as Chief Financial Officer
Business Wire - Mon Nov 10, 6:00AM CST
bluebird bio, Inc. (Nasdaq:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced that James M. DeTore is joining the company as its Chief Financial Officer and Treasurer and member of the company's leadership team.
BLUE: 39.14 (-2.09), IRWD: 13.13 (-0.36)
bluebird bio to Present at Three Upcoming Health Care Conferences
Business Wire - Fri Nov 07, 6:00AM CST
bluebird bio, Inc. (Nasdaq: BLUE) announces that management will present at the Credit Suisse First Boston Bank Health Care Conference on Thursday, November 13, 2014 at 8:00 AM (MST) at the Biltmore Hotel, Phoenix, Arizona. Management will also present at the Deutsche BioFEST Conference on Monday, December 1, 2014 at 9.50 AM (ET) at the Four Seasons Hotel, Boston, Massachusetts and at the Piper Jaffray Healthcare Conference on Tuesday, December 2, 2014 at 3.30 PM (ET) at the New York Palace Hotel, New York, New York.
BLUE: 39.14 (-2.09)
Update: New Patient Receiving BlueBird Gene Therapy Responding More Slowly
at The Street - Thu Nov 06, 10:31AM CST
The new clinical data on Bluebird's gene therapy is contained in a just-released abstract ahead of next month's American Society of Hematology (ASH) annual meeting.
BLUE: 39.14 (-2.09)
Bluebird Bio (BLUE) Highlighted As Weak On High Volume
at The Street - Thu Nov 06, 9:01AM CST
Trade-Ideas LLC identified bluebird bio (BLUE) as a weak on high relative volume candidate
BLUE: 39.14 (-2.09)
bluebird bio to Present LentiGlobin Clinical Data at the American Society of Hematology Conference
Business Wire - Thu Nov 06, 8:01AM CST
-- Data to be presented from the Northstar Study and from the HGB-205 Study
BLUE: 39.14 (-2.09)
Insider Trading Alert - BLUE, CHRW And BMY Traded By Insiders
at The Street - Wed Oct 29, 9:06AM CDT
Stocks with insider trader activity include BLUE, CHRW and BMY
BLUE: 39.14 (-2.09), CHRW: 73.07 (-0.04), BMY: 57.95 (+0.15)
Can the Uptrend Continue for Bluebird (BLUE)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 8:22AM CDT
Can the Uptrend Continue for Bluebird (BLUE)?
BLUE: 39.14 (-2.09)
Will Quest Diagnostics (DGX) Surprise Earnings in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 2:30PM CDT
Quest Diagnostics Inc. (DGX) is scheduled to report its third-quarter 2014 results before the opening bell on Oct 23.
BLUE: 39.14 (-2.09), MDVN: 106.90 (-0.31), PACB: 6.80 (-0.13), DGX: 62.41 (-1.36)
Will Zimmer (ZMH) Miss Earnings Estimates this Quarter? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 2:10PM CDT
Zimmer Holdings Inc. (ZMH) is scheduled to report its third-quarter 2014 results before the opening bell on Oct 23.
BLUE: 39.14 (-2.09), MDVN: 106.90 (-0.31), ZMH: 110.12 (-0.49), PACB: 6.80 (-0.13)
Will Boston Scientific (BSX) Surprise this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 2:20PM CDT
Boston Scientific Corporation (BSX) is scheduled to report its third-quarter 2014 results before the opening bell on Oct 22.
BLUE: 39.14 (-2.09), MDVN: 106.90 (-0.31), BSX: 13.36 (-0.05), PACB: 6.80 (-0.13)
InsiderInsights.com Daily Round Up 10/14/14: ALSN, ETE, AAMC, AGCO
InsiderInsights - at Seeking Alpha - Wed Oct 15, 10:08AM CDT
BLUE: 39.14 (-2.09), RDEN: 17.41 (-0.29), AGCO: 44.18 (+0.09), ALSN: 33.37 (+0.16), AAMC: 481.00 (-10.84), ETE: 61.69 (+0.77), BURL: 42.30 (+0.04), SHLD: 37.31 (-0.49), GOOG: 544.40 (-0.98), VNO: 107.58 (-0.57), OPK: 8.29 (-0.05), CUDA: 35.34 (+0.98), COST: 138.48 (-0.23), WMB: 54.05 (+0.17), FTK: 22.03 (+1.38), WAG: 66.93 (-0.03), SYK: 88.00 (-0.84)
bluebird bio Announces First Patient with Sickle Cell Disease Transplanted with LentiGlobin Gene Therapy
Business Wire - Tue Oct 14, 6:00AM CDT
bluebird bio, Inc. (Nasdaq: BLUE) a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced that the first subject with severe sickle cell disease has undergone infusion with bluebird bio's LentiGlobin BB305 drug product in an autologous hematopoietic stem cell transplantation. This patient is enrolled in the HGB-205 Study being conducted in Paris, France. bluebird has also opened a separate US-based trial (HGB-206) in the United States for the treatment of up to 8 severe sickle cell disease patients with the company's LentiGlobin BB305 drug product.
BLUE: 39.14 (-2.09)
Insider Trading Alert - BLUE, NVAX And SNCR Traded By Insiders
at The Street - Mon Oct 06, 9:15AM CDT
Stocks with insider trader activity include BLUE, NVAX and SNCR
BLUE: 39.14 (-2.09), SNCR: 48.38 (+0.42), NVAX: 5.28 (+0.09)
Acceleron Hit Over Competitive Concerns, But Investors Overlook Rest of Pipeline
at The Street - Thu Oct 02, 8:21AM CDT
An Acceleron update in December could reignite investor interest in the stock.
BLUE: 39.14 (-2.09), XLRN: 33.50 (-1.81)
Global Gene Therapy Market Outlook 2018
M2 - Wed Sep 17, 5:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bqlkd5/global_gene) has announced the addition of the "Global Gene Therapy Market Outlook 2018" report to their offering. Gene therapy is the treatment of a disease by replacing, altering, or supplementing a gene that is absent or abnormal and whose absence or abnormality is causing the disease. It has evolved as one of the most sought after research objectives for difficult to cure' diseases. The gene therapy market, presenting a few marketable products and being nascent in terms of revenue generation, holds tremendous growth potential. As per a new estimation carried out in our latest study, the global gene therapy industry has the potential to become a multi-million dollar industry by the end of 2018, as new products, especially those in the advanced stage of clinical studies or with pending approvals, may enter the market to boost the growth. Primarily, the gene therapy market is dominated by oncology applications with several companies and academic institutions focusing on novel and difficult to treat' cancers. Other therapeutic areas seeing developments in gene therapy include cardiac conditions, inherited blindness, genetic disorders and neurological diseases. An effective analysis of the key therapeutic areas has been included in the report. Also, a brief overview of the key geographies in the gene therapy market and the regulatory scenario governing the industry has been included to present a balanced outlook. Unlike other regions globally, the United States continues to have the maximum number of clinical trials in the gene therapy segment. This shows the country's potential to become a leader in gene therapy in the coming years. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Gene Therapy - An Introduction Classification of Gene Therapy Techniques Physical Methods of Gene Transfer - Electroporation - Hydrodynamic - Microinjection - Particle Bombardment - Ultrasound-mediated Transfection Vectors for Gene Therapy - Adenoviral Vectors - Adeno-associated Virus Vectors - Retroviral Vectors - Lentiviral Vectors - Plasmid DNA 4. Industry Trends and Drivers Industry Trends - Gene Silencing: Gaining Momentum - Advanced Therapies: Combining Gene Therapy and Stem Cell Technology - Immunodeficiency Syndromes: The Focus of Gene Therapy - Nanotechnology: Empowering Gene Therapy - Gene Therapy: A New Hope to Treat Blindness - Gene Therapy: Potential Cure for Cancer Market Drivers - Failure of Conventional Therapies to Treat Cancers - Entry of Gene Therapies in Developed Nations - Rising Incidence of Chronic and Life Threatening Diseases - Growing Interest of Venture Capital Firms 5. Market Restraints - High Cost of Treatment - Stringent Regulatory Laws & Safety Concerns - Pitfalls in Current Technique 6. Gene Therapy Market Outlook - Oncology - Infectious Diseases - Genetic Disorders - Cardiovascular Disorders - Diabetes Mellitus - Neurological Disorders 7. Gene Therapy Market - Regulatory Landscape 8. Advanced Gene Therapy Drugs - Collategene - Allovectin-7 - Generx - Glybera 9. Mergers and Acquisitions - Sangamo BioSciences to Acquire Gene Therapy Company Ceregene. - Baxter to Acquire Chatham Therapeutics - Bluebird Bio Acquired Privately Held Gene-Editing Company - Miltenyi Acquired Gene Therapy Assets from Lentigen - Dutch Player UniQure to Acquire InoCard GmbH for CHF Therapy. 10. Key Players Analysis (Business Description, Clinical Pipeline, Recent Developments, Strengths & Weaknesses, Key People) - Spark Therapeutics, LLC - ViroMed Co. Ltd. dba VM BioPharma - Advantagene Inc - Bluebird Bio - Sanofi - Genzyme - A Sanofi Company - Kolon Life Science - Vical Inc - Oxford BioMedica - Genethon For more information visit http://www.researchandmarkets.com/research/bq...lobal_gene
BLUE: 39.14 (-2.09), VICL: 1.12 (-0.02), SGMO: 11.21 (-0.52)
